Overview

Assessment of Safety, Tolerability and Drug Levels of NPM-119 in Participants With Type 2 Diabetes

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and drug levels of a 3-month exenatide implant (NPM-119) for the treatment of type 2 diabetes
Phase:
Phase 2
Details
Lead Sponsor:
Vivani Medical, Inc
Collaborator:
Medpace, Inc.
Treatments:
Exenatide